KIDNEY CANCER CARE LIMITED (A cornpany limited by guarantee) TRUSTEES, REPORT AND FINANCIAL ST ATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 KIDNEY CANCER CARE LIMITED FINANCIAL STA TEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 CONTENTS AND ADMINISTRATIVE fNFORMATION CONTENTS PAGE., Trustees, Report Independent Exatjiner's Report Statement of Financial Acttvitieg Balance Sheet Notes to the Finanrial Statements 8-16 TRUSTEES,, B J Greenwood (Chainnall) NICOX DrJNPerry Prof G D Stewart CDThon Dr N Charnley GFOX G Oades Dr E Boleti Prof M Tran COMPANY SECILETARY AND CHIEF OPERATING OFFICER: M Packer REGISTERED OFFICE.. 4 New Imi L￿e Guildford Su￿eY GU4 7HW COMPANY NUMBER., 05937304 CHARJTY INCORPORATION NUMBER,, 1120146 and SC043642 tNDEPENDENT EXAMINER: Tall Shipley FCCA For and on behalf of; Prentis & Co LLP Chartered Accountants & Iiidependent Examiners 115c Milton Road Cambrkdge CB4 IXB PRESIDENT.. J Whale MBE HONORARY VICE PBESIDEM'S.. Earl Freddie Howe Tim O'Brien PATRON.. Td Addington KIDNEY CANCER CARE LIMITED PAGE I FtNANCIAL STA TEMENTS FOR TFIE YEAR ENDED 30TH SEPTEMBER 2024 TRUSTEES ANNUAL REPORT The Trustees present their annual report together with the finanGial staten]ents of the charity for the year ended 30th September 2024. The annual report serves tbe purposes of both a Trustees, Report and a diTQrtors report under company law. The Ti￿teeS confirni that the atinual report and fmancial 5tatsments of the Charitable cOmp￿Y comply with the current statutory requirements, the requirement5 of the charitable GomptLny's gov¢n]ing document and the provisions of the Statement of Reconunended Practice (SORP) applicable to charities preparing their accounts in accoTdance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effectivo 1st January 2019). Since the charity qualifies &s small under section 382 of the Companies Act 2006. the str&togic report required of mediu d large companie5 under the Companie5 Act 2006 (Strategie Report and Directors, Report) Regulations 2013 has btten c OBJECTIVES AND ACTIVITIES AND PUBLIC BENEFIT Pollcies and objectlves Thu puliGiLs Ewd obj¢ctives of the charity &re set and agreed at the charitys AGM which 15 held each year end. They focus on providing support for kidney canLer patients and their carers, raising awareness of thL disLaso umongst the professional health conllT]unity, the general public and government health plannin¥ audicnces. In 8etting obj￿tiveS and planning for activities, the Trustees have giv¢n due consideration to general guidono¢ published by the Charity Con]mis5ioTh relating to public benefit, including the guidance 'Publi¢ benefit,. runnlng a charity (PB2)'. ACHIEVEMBNTS AND PERFORMANCE Review of activities IntroduclAon to Kidney C￿cer UK'S Finallcial Statement for 2024 As we reflect on 2024, it is with inunense gratitude that we acknowledge the dedication and hard work of every momber of the Kidney Cancer UK t#am. Their commiiment has been key to our progress this year, and l am deeply appreciative of theAr contributions. Since the arrival of our new CEO 18 months abro, the charity has undergone a transfonnation, becomTrng leaneT, more dynamic, and effectlve. Our is now based in Gutldford, Su￿¢Y, and we antLClPtite modest groH¢h in the cominE Ye￿ as our offiLC-ba%'Ld staff, currently Standing at three, expands to better support our mission. While NHS services contin.ue to face immense pressures - Struggling to address the backlog caused by the pandemic and industrial action - we remain steadfdst in our focus on supporting kidney cancer patients, their families, and caregivers. Our efforts airn to mitigate the impact of treatment delays on p&tient well-being and has seen us calling on the NHS to use our, and other Speci￿1st Lancer charities, routinely. Throughout the yoar, our free telephone Support Line has reLnained an important well used resourc¢, though we have seen a shift towards increased engagement within our active closed Facebook groups. The dem&nd for our free coun5elling 5ervic¢ remains high, &nd although & small waiting list has emerged, we have been &ble to m¢¢t the demand whilst remaining within our current resources. Our digital prtt5ence continues to thriv#, with nearly 3,000 members in our four closed Facebook groiips, fostering tnvaluable sense of community. We are continuously cxploring new ways to improve OUT ollline offerings to meet Ihe needs of those we serve. addition, we launched a new Healthcare Professional website in Septernber 2024, which is Steadily gailling membership and now stands close to 500 users, The 2024 Kithgy Cancer UK Patient Survey, released during Ki(Iney Cancer Awareness Week in February, highlights persistent Issues such as incidental diaglloses and widespread dissatisfaction with NHS information and support. This reinforces our focus on improving patient experience and ensuring they receive the care and inforniation they need. A notable concern froEn the survey was that 630/0 of patignts did not receive a Cancer Care Review from their GP within three monlhs of diagnosis antvor three mi)nths of acute treattnent as is required as per NHS England KIDNEY CANCER CARE LIMITED .PAGE 2 FfNANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 TRUSTEES ANNUALREPORT................................lCONT￿uED ACHIEVEMENTS AND PERFORMANCE - continued QuaIity Outcome Fram¢woilc (QOF), The NICE guideline (for which we successfully campaigned) is progressing well and we allticipat¢ that it will be published in 2026. Thi8 will be a inajor milestone seeing the National Institute for Health and Care Excellen¢e (NICE) publish the r￿St-ever n&tional guidelines for kidney cancer. Separately, the National Kidney Cancer Audit is now fully active and made its fJTSt annual roport in September 2024. sO￿e of tho indicators 115ed in the audit were based on our audit work. Despite the challenges posed by ￿ndraIsing, the charity remains on a stable footing and is well-positioned for the next phase of ￿oWth. We are committed to overcoming Current obstarles by intsnsifying our fimdr&ising efforts and exploring new opportunities. OUT ultimato goal is to not only build our vital patient services blrt to continue evolving as the leading forc6 in kidney cancer patient support and advocacy in the UK. FINANCIAL REVIEW a. Golng ¢oneern After malcing appropriate enquiries, the Trustees havo a re￿Onable expectation that the charity has adequate resources to continue in operatic)nal existence for the foreseeable future, For this reasoT], they Gontinue to adopt the goin8 concern bY45iS tn preparing the financial statemenls, Further details regarding the ttdvption of th¢ going concern basis ¢&n be found in the a¢countillg policies. b. Reserve¥ pollcy The clwity received total income of £289,934 (2023.. £254,102), il expended £223,802 (2023., £323,221) and had an ovordll surplus of £66,132 (2023: deficit £69,119). Reserves stand at £152,759 (2023: £86,627), comprising unrestricted reserves of £84,445 and restricted reserves vf £68,314. 'lThe charity had free reserves of £84,445 (2023,. £76,972), The Trustees liave considered the level of free reserves that the charity holds, whith eurrently stands &t six months of our operating costs. It is their intention to bulld those further going forward. STRUCTURE, GOVERNANCE AND MANAGEMENT a. ConstltutlOD Kidney Cancer Care Limited is registered charitable company limitad by guaruntee and was Set up by a Memorandum of Association on 15th September 2006. It is registered with the C1)￿lty Commiy5ion for England and Wales nurnber 1120146 and Office of the Scottish Regulator number SC043642. b. Methods of appointJneDt or election of Trustees The management of the charity 15 the r￿ponsIbIlity of the Trustees who are elected and co-opted under the tenns of the Memorandum of As80ciation. The Trustees who served during the year w¢re', B J Greenwood {Chairnian) NICOX DrJNPery Dr G D Stewart C D Thoma5 Dr N Ch&mley GFOX G Oad¢s Dr E Boleti Prof M Tran KIDNEY CANLER CARF: LIYI ITED PACIE 3 FINANCTAI.. s'fAT1￿* FNI'S FQR TklE YF.AK EWI)fD 301'FI SEPTF,Mt4F.R ?624 TRU5TEÈ,S ANNUAL Rk"PC)RT ,.. .,ICQNI'INUbD STrUL:IYJR.F., (iQVERNANC,I, AND MANAGFMENT - ¢ontinu¢d e. Organl$¥tlon#l %tructutt and poll¢lo Th¢ day.to-48y lies wlth the tsfflc¥ of tba ¢h%rity's C.hiofOp¢ratini Of4ice (COO) avtbw liE)¢ wlth Iho obj,#dlve% 18yeed.by the Board of'T'rnytees. The L'QO repnrt% lo th¢ L'h#ii of th# BKJwd when ttqutr¢fl btj&f¥ 4)£her kn¢mbws ol'the Buard, The Bo4Yd ofTYuakos Ari*¢ts 4U4rt¢rly and Is ¥uppurted by the ¢harity'B yenioi teavi, Our Tru%te¢s are drmwn from 4 rftngo ol prof¢8YioDal b&¢ksToundy bring & wlde rEm8e orrttl&Va￿t *xperi¢llc¢. d. MLmbttrs* Ilabllity The m¢￿berS ot tho Oh￿[ty guart4ntLe lo ¢ontribu¢e Ainvunl Dot ¢xct¢dliig El to thé dss?ts ot ohBri1y t th¢ Lvttllt ot windly1￿ up. SI'A TEMEN1' OF TRUS'I'EES, KkSPONSIBIL.I'I'IES The Trustot¥ {who w¢ al#0 th¢ dlr¢ots)rs of tli¢ churity for Llitt purpoyès Jf vompony l#w) respoDsible for preparing tk#'frugl#e5 Rvport and the fijwittlal stut¢monts in 4¢¢0rdun¥e wlth appllcable law United Kingdom AocountiAg Siantjurds (Unlted Kin%dom (Jtnorally AK4pi.ed A¥Wlmtl.ng PracilLC), Company l&w requlr¢% th4 I'nLitstss lo p.v¢pu¢ ihe financi&l Ststomonts for iatth ￿)unCl,￿l yfflw, Und&r ¢OtrJpany Iiw, th4 Trust¢es uJiiSI IIQI tLPPYOV¥ thts firwvcknl grdi¢n)¢nts Ih ob$urve tho m¢ihvdx and prhi¢lpuls of tho LThdrlfifjTs 8ORP (rRs102); ni8ka judg¢nJeutg 8ncl Motvuutlng esrlmute5 that aro r¢aioLiJbl¥ Ind p￿￿thI; ltafe wheth¢r applierible UK Aoioutttlng S'tdndurd5 (F'RS102) h&ve be¢n folloived, subject to r&ny mat#rlAI d¢pttrfiwe4 dlscloyed wid oxplulned in the ¢inanLi&l stst¢m¥iits; prnpartt the finun¢iul 618t*ineyJl% (ill ft uoln¥ Goncern b45is unl¥&8 it is in&ppry)pri#te to p￿Su1￿¢ th? Chllrfiy WIII Colltinuo in op¥rntlon. (¥) The 'l'rusie&% &r* rrypontslble fo.r ke¢pinkA adequal¢ ttLXUWlting rocnrds thul Iwe siiificiellt ts) and ÉxpluiN the clillrily'% tr#n8 ions disclts&* with reusonllble YkLLura.¢y &t ￿LY tim¢ fin&ncial pabltion of the i'hwity nd enublo ihem tu ell8ilto tliai tlir finaiicial st2ttttTM¢iJl* oomply wltJJ tho Comp4nles Act 2006. They &rg re¥pon¥ible for 3af£%uku'ding ti)a asse¢8 of thtt charlly hence for taklu% ro#s0￿ble step8 far th¢ provenlion #nd d#t¢Ltion oftrll(Id and other irr¢sul&rltlos, Approvttl by tsrder of the iil¢iiLbttts Of tli¢ Board uf Tru%ites ond $18ll¢d on their b¢h4ifby; B J tiEiEE CHATRMAN KIDNEY CANCER CARE LIMITED PAGE 4 FINANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 INDEPENDENT EXAMtNER'S REPORT TO THE TRUSTEBS OF KEDNEY CANCER CARE LIMITED I report to the charity Trustees on my examination of the accounts of the charity for the yeaT ended 30th Septsrnber 2024. RESPONSIBILITIES AND BASIS OF REPORT As the Trustees of the charity (and its directors for the purposes of corllpany IY4W), you are responsible for the prep￿atiOn of the a¢couDts ill 8¢Gordan¢e with the reqltirernents of the Charities and Tn)stee Investment (Scotland) Act 2005 ('the 2005 Act,), the Charities AGcounts (Scotland) Regulations 2006 (as amended) ('the 2006 Accounts Regulations,) and the Compani¢5 AGt 2006 (Ihe 2006 Act,). You are satisfied that the accounts of tbe charity are not required by charity or company law to be audited and h&ve chosen instead to have an independent examination. Having satisfied myself that th¢ accounts of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in resp¢ct of my exarnination of the charity's accounts c￿Tled out Lmder section 44(1)(c)of the 2005 Act and sethion 145 of the Charities Act 2011 ('the 201 l Act,). In carrying out my examination I have followed tbe requirements of Regulation I I nf the 2006 A¢count$ Regulations and the Directions given by the Charity Commission undLf SLLtion 145(5)(b) of the 201 l Act. INDEPENDENT ELIMINER'S STATEMENT Since the charity is required by cornpany law w prepare its accounts on an accrual basis and is registored as a charily in Scotland, your examiner must be a member of a body lisled in Regulation I1(2) of the 2006 Accounts R¢&Fulations. I call confirm that I am qualified to undertalce the examination because l am a registered member of the Association of Churtered Certified Accountants, whlch is one of the listed bodies. have completed rlly examination. I confwm that no material matters have come to my attention in connection with the examination giving me oause to believe that in any material respect., accounting records were n()t kLpt In respetit of the charity a8 required by section 386 of the 2006 Act and ￿L￿UlatIO11 4 of Ibe 2006 Accounts RegLilations,' or tlic uLL()unts' do not aCLord with those records and with the accounting requirements of Regulation 8 of the 2006 Account5 R¢gulations' or the accounts do not comply with the accounting requirements of section 396 of the 2006 Acl other than any requirement that the accounts give a 'tnie and fair, view whi¢h is not a matter considered as part of an independent exaffjination,. or the accounts have not been prepared in accord￿Ce with the methods and principles of the Statement of Rerommended Practice for accounting and reporting by charities [appli¢able lo charities preparing tbeir aCCOUllts in accordance with th¢ Fillancial Reporting Standard applicable in the UK and Republic of Ireland (FRSI 02)]. I have no concerns and have come across no other matters in Gonllection with the examination to which attentii)n should be dramjn Èn this report in order to enable a proper understanding of the a¢¢ounts to bc reaGhed. KIDNEY CANCER CARE LIMITED PAGE 5 FINANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 INDEPENDENT ELIMINER'S REPORT TO THE TRUSTEES OF KIDNEY CANCER CARE LIMITED This report is made 501ely to the Gharity's Trustee8, as a body, in accordance with Port 4 of the Charities (Accounlb and Rcports) Regulations 2008 and Regulation I l of the Charities Accounts (Scotland) Regulations 2006. My work h&8 been undertaken so that I might state to the ¢harity's Trustees those rnatters I am required to stst¢ to them in an indeperkdent examiner's report and for no other purpose. To the fullest extent perniitted by law, I do not &ccept or assume responsibility to anyone other than the charity and the cl]aritys Tru8tees as a body, for my work OT this report. IAN .8HIPLEY FCCA FOR AND ON BEI-IALF". PRF,NTIS & CO LLV CHARTERED ACCOUNTANTS & INDEPENDENT EXAMINERS 115¢ Milton Road Cambridge CB4 IXE J ¢ K14JNIYCANCEK CARV, LIMI1.￿D INANCIrtI.,STAtENIENtS FOR I'HE YEAII tNDF.D 36TH SF3P'ftsMtsEk 20J4 BALANCE sHpJir 2024 No(ts FIXFD AsgBTS T￿251b[￿. ass¢ts CUIIREKf AS%I.'TS 3,164 4,26-5 15,738 Dttbtors c'#$h ai bank ittd In h4ftd 16ei,f)31 16É),798 TOI."AL CUIIRÉNT AbSII'S I l L,457 C'URRENT LI,4R.TLI'fiF,S Crodltor8', Amaunts fklllDg duL wlthin vne year 17,Q39 NET CURRbNT ASSETS 152.759 86,627 TOTAL NET ASSETS 152,759 86,627 'riiF. fuNDS 011 THI CIIARITY li￿3tn'ct¢d fun(t8 lJnr¢8trioted funds 12 68,314 84,445 9,65S 76,972 TO'fAL C'14AKII'Y17UNDS 152,759 86,627 Tlie dlre¢tors tton$ldLY thyt th¢ ¢hurit#ble coÉllp&ny 1$ &ntltled to txèmpduii the toqulromtht. w hav4 *14udll und¥r th¢ provisionj of 47711) 41 the LonJp3￿Je9 A¢1 2006. hav¥ ntjt r¢qutred ¢t)mwy uttder SffLtion 476 orth¢ ¢L)fbp&ni¢s A¢t 2QD6, 10 obtain On xiidlt for the yrar tn6vd 30th Supicniber 2024. 1ke dir¢¢tols ackn17wl#d¥e thei# ttspoiisibilitl¢8 f(br ¢ttywing that Ili¢ ¢harit#hl¢ c(iJnpttqv kpeps wounVI.whu r￿C￿rdS whtih oomply with Stctlon 3#6 Imd 281 olthe C,'ollipuhie$ A¢t 2006 and &Jt prepgriiig fmanci%il .4lthlethints which gl¥¢ auue and thir vI¢w orih¢ stllttt of uffLir8 Ot tho tharStatsle compttny al 3rJth Sei>t¢mbllr 2024 tll)d Of its Iiwplus Cor lh¢ y¥Hr th14D ¢nd(Jd io d¢&o.rda]]tso with thtTe4ul¥tsbnY¢tsi¥ S*tiott 396 Mnd wliiob (ithèfwi￿ e(iinply Wtyh th* le4￿1r¢M¥ms, Df the. Ai relatlng to Ihe fiuan¢ial &t￿l¢m¢￿t$ lknr ￿ opplicable tn the c,h*rlidbl'e Guinpxny. 'rh¢ fiThunciaT 3t&temeiiis, wlloh have b¢on prepir¢a in a¢borddtLc with tlie 5p¢clal provlylo115 ¥Llatiriu tsi.wwpw)l£s yubjtct to tht s.mall ¢orr4PLuiles. rcgini¢ within P¢rt 15 oEth¢ LompaÉiie.4 Aot 2QOfi, wttr# 4p.pmv&d by the bo#r4 Cfrl 21 LS aD£I >ignod 011 Iiy b¢half, EIJGRB CHAIIifvL4N '11iL notos on pogiy 8 to 16 fornj part Of IhesL financial 8talvments. KIDNEY CANCER CARE LIMITED PAGE 8 FfNANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FINANCtAL STATEMENTS ACCOUNTtNG POLICIES (a) BASIS Of PREPARATION OF FNANCIAL ST ATEMENTS The fLnancial 5tatsments have been prepared in accordance with the Charities SORP (FRS102) - Accounting and Reporting by Charities.. Statement of Recommended Practir¢ &pplicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Eiepublic of Ireland (FRS102) (effective 1st January 2019), the Financial Reporting Standard applic&ble in the UK and Republic of Ireland (FRS 102), Companies Act 2006, Tlie Charities Accounts (Scotland) Regulations 2006 and the Charities and Trustee Investment (Scotland) Act 2005. Kidney Cancer Care Limited meots the definition of a public benofit ¢nTity Lthder FRS102. Assets and 1ip4bilitie8 are initially recognised at historical coyt or transaction value unless otherwis¢ stst¢d in the relevant accounting policy. The financial ststements are presented in sterling, which is the functional currency of the charity. The Trustees have taken adv￿tage of the amendn]ent to the Charities SORP FRS 102, where only larger charities are required to prepare V4 Statement of Cash Flow5. (b) CHAIiITY STATUS The charity is a company limited by guarantee. Tbe members of the charity are the Trustees. In the event of the charity being wound up, the liability in respect of the guarajitee is limited to £1 per member. (c) INCOME All incorne is reco￿ls¢d once the ch&rity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be mea8ured reliably, Th¢ recognition of income from legacies is dependent on establishing entitlement, th¢ PTobability of receipt and the ability to estimate with sufticiont accuracy the amount receivable. Lvidence of entitlement to a legacy exists wh¢n the charity has sufticient evid¢nc¢ that a gift hag bcen left to them (through l(nowledge of the existence of a valid will and the death of the benefactor) th¢ executor is satisfied that the property in question will nol be r¢quired to satisfy claims in the estate, Receipt of a legacy must be recognised when it is probable that it will be received and th¢ fair value of th¥ amount re¢eivJble, which will generally be the expected cash amount to be di8tributed to the charity, can be reliably measured. Grants are included in the Statement of Financial Activiti¢s on a receivable basi8. The balance of income received for specific purposes but not expended during the period is shown in the relevant fund on the balance sheet. Where income is reGeiv¢d in advance of entitlement of receipt, its reCO￿lt10n is deferred and included in creditors as deferred incom¢, WheTe mtitlement occurs bEfore income is re¢eiveLt the income Es a¢Grued. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the tirne of donation. Income tax recoverable in relation to InveSt￿ent income is recognised at the lime the investment in¢ome is rec6ivable. Other income is recognised in the period in which it is receivable and to the ¢xt¢nt the goods have been provided or oll cO￿PIet10ll of the seTVlCe. KIDNEY CANCER CARE LIMITED PAGE 9 FINANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FINANCIAL STATEMENTS ACCOUNTING POLICIES - Continued {d) EXPENDITURE Expenditure js recogDi5ed once there is a legal or constructive obligation to transfer the economic benefit to a third paty, it is probable that a transfer of economic benefits will be reqLJired in settlement and the amount of the obligation can be measured reliably, Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating infoTtnation in support of charitable activities. Governance costs are those inLurred in connection with administration of the Fund and cornpliance with constitutional and statutory requirements. Expenditure on charitsble activities is incurred on directly undertaking the actlvities which further the charity's objectives. as well as any associated support costs. Grants pay&ble are charged in the year when the offer 15 made except in those c&ses where the offer is conditional, such grants being recognised &s expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a ornmitmen( but not accrued as expenditure. (e) TANGIBLE FIXED ASSETS AND DEPRECIATION Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fLxed assets are measured at COSt less ac¢umul&t¢d depr¢ciation and aiiy accumulated impairnient losses. All costs to bring a tangible fixed ai3$et into its intended working condition should be included in the measurement of Cost, Depreciation is ch￿ged 80 as to allocate the cost of tangible fixed assets less their residual value OVLr ib¢ir ￿tiMated us¢ful liv¢s, using th¥ ¥trui¥bt-luiL m¥thL) Depreciation is provided on the following b&sis'. Plant and rnachinery 500/0 Straight line (fj OPERATING LEASES Rentals paid under op¢rating leases are Lharued to the Statement of Financial Activities on 8 straight line basis over the lease terni. (g) PENSIONS The ch&rity contributes to personal pension pltms of its employees and the pension Ch￿'ge represents the amounts payable by the charity to the plans in respect of the year. (h) FUND ACCOUNTtNG General funds are unrestricted which are availabKe for use at the discretion of the Trnytees in furtherance of tlie general objective8 oFthe charity and which have not been deS1￿￿ted for other purposes. Restricted fimds are fL￿dS which are to be used i.n accordance with specific restrictions imposed by donors or which have beeTh raised by the cbarity for particular purposes. The costs of raiging and administering such funds are charged against the sp¢¢ifi¢ fund, The aim and use of each restricted fund is s¢t Out in the notes to the financtal statements. n r/J rtt U # # ) 4¥ b) J C UJ o c NJ ¥0 L* bJ ¥0 LJ) ¥ CtXQ C C KIDNEY CANCER CARE LIMITED PAGEII FINANCIAL STA TEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FINANCIAL STA TEMENTS INVESTMBNI fNCOME Current year Restricted Unrestricted Funds Funds 2024 2024 Total Funds 2024 Bank interest receivable 1,096 1,096 Restricted Unrestricted Funds Funds 2023 2023 Total Funds 2023 Prior ye4r Ballk interest receivable 538 538 ANALYSIS OF liXPFNDITURE ON CHARITABLE ACTIVITIES Restricted UDre5tricted Summary by fund type Fw1ds Funds Current year 2024 2024 Total Funds 2024 Patient &dvice and inforniation 5UPPOrt services Fundraising 19,500 186,781 206.281 l32 17,3 89 17,521 19,632 204,170 223,802 Restrictgd Unrestricted Funds Funds 2023 2023 Total Funds 2023 Prior year Patient advice and inforn]ation 5UPPOrt services Fundraising 32,280 256,813 289,093 34,128 34,128 32,280 290,941 323,221 ANALYSIS OF EXPENDITURE B Y ACTIVITIES Current year Activities Grant undertaken fimding of Support directly ￿tivitIeS Cost 2024 2024 2024 Total fimds 2024 Patient advire and infonnation support services Fundraising 195.130 17,521 1.500 9.651 206,281 17,521 212,651 1,500 9,651 223,802 KIDNEY CANCER CARE LIMITED PAGE 12 FINANCIAL STA TEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FtNANCIAL STA TEMENTS ANALYSIS OF EXPENDITURE B Y ACTIVITIES - continued Activities Grant UDdertakttn funding of Support directly activities Cost 2023 2023 2023 Prlor year Total funds 2023 Patient adviGe and inforniation support services Fundraising 276,146 34,128 12.947 289,093 34,128 3 AO,274 12,947 323,221 Analysis of direct costs Current year Patient support and infornation FU[￿rAISIng 2024 2024 Total fimds 2024 Staff Costs Fundraising costs Establisl)ment costs Bank charges Patient support Printin& postage and stationery Subscriptions and donations Repairs and maintenance Travel and subslstence Advertising and promotion Training> conference and meeting costs Jnsurance Rent and rates Website and internet expenses Sundry expenses 109,735 109,735 17,521 3,593 354 12,578 9,276 1,274 65 2,680 26,046 177 R84 5,442 23,013 13 17,521 3,593 354 12,578 9,276 1,274 65 2,680 26,046 177 884 5,442 23,013 13 195,130 17,521 212,651 KIDNEY CANCER CARE LIMITED PAGE 13 FINANC.tAL STATBMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FINANCIAL sTATE￿NTs ANALYSIS OF EXPEIqDITURE BY ACTIVITIES - continued Analysis of direct eosts Prlor year Patient support and inforn]ation Fundraising 2023 2023 Total funds 2023 Staff costs Fwidraising costs Establishment costs Bank charges Patient support Printing> POStag¢ and stationery Subscriptions and donations Repairs and maintenance Travel #nd,%ubsi¥tenig Advertising and promotion Training, conference and ineeting costs Insurance Rent and rates Website and uiternet expense5 Sundry expenses 199,609 199,609 34,128 34,128 5,083 426 l6,7l7 8,011 1,347 728 3,701 19,045 279 1,069 13,291 6,195 645 5,083 426 16,717 8,011 I,347 728 3,701 19.045 279 1,069 13,291 6,195 645 276,146 34,I28 310,274 Analysis of support costs Current year Patient support and inforniation 2024 Total funds 2024 Depreciation Professional fees 9,651 9,651 9,651 9,651 Analysis of sllPPOrt costs Prior year Patient support and infonnation 2023 Total ftjnds 2023 Depreciation Professional fees (incl. IE fe¢s) 781 781 12,166 12,166 12,947 12,947 KIDNEY CANCER CARE LIMITED PAGE 14 F￿ANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FtNANCIAL STATEMENTS STAFF COSTS 2024 2023 Wages and salaries Social security costs Penslon costs Other staff costs 98,090 127,577 2,777 5,054 3,883 23,453 4,985 43,525 109,735 199,609 The average number of personal employed by the charity during the y¢ar was as follows., 2024 2023 Patlent care and admin No employee received remuneration arnounting to more than £60,000 in either year. TRUSTEES, REMUNERATION AND BXPENSES During the y¢ar ended 30th SeptLmbLT 2024 no Trustees received any remuneration or other benefits (2023. £Nil), During the year ended 30th September 2024 no Trustee expens¢s have been incurred (2023: £Nil). FIXED ASSETS . Plant and Plant and Machinery Machinery 2024 2023 COST OR VALUATION At 1st October Additions 5,862 5,862 Balance at 30th September DEPRECIATION At 1st October Charge for tbe period Balanc¢ at 30th September NET BOOK VALUE AT 30th September 5,862 5,862 5,862 5,081 781 5,862 5,862 STOCKS 2024 2023 Goods for resale 3,164 4,265 io. DEIBTORS Due wlthin one year Prepaymellts alld accrued income 2024 2023 6,003 15,738 KIDNEY CANCER CARE LIMITED PAGE 15 FINANCIAL STATEMENTS foR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FtNANCIAL STATEMENTS CREDITORS Amounts fHllin2 due wlthin one year Tr&de creditors Other taxation and social security Other creditors Accruals and deferred income 2024 2023 928 993 5,554 1,077 611 17,588 14,007 17,039 24,830 12. STATEMENT OF FUNDS Currentyear Balance at Balance at 1st 30th October September 2023 Income Expenditure 2024 Uttrestricted funds General Funds 76,972 211,643 (204,170) 84,445 Reitrlcted fund8 Kidney Cancer A wareness Research Grants (University of Cambridge) HealthLare Professional Website redevelopment Private donations for Research 9,607 61,666 1,500 15,000 125 (9,607) 61,666 (1,500) (8,400) (125) 78,291 (19,632) 68,314 86,627 289,934 (223,802) 152,759 6,600 48 48 9,655 TOTAL OF FLfNDS STATEMENT OF FUNDS Prior ycar Balance at Balance at 1st 30th OctobLr September 2022 Illcome Expenditure 2023 Unrestrlcted fund5 GeneTal Fund5 119,859 248,054 (290,941) 76,972 Restrlcted funds Kidney Cancer Awareness Drop-in Centre Fund CEO Retirement Fund Web Redevelopment Grant House of Lords Grant Private donations for R¢search 5,642 3,000 15,000 i.ioo i 0,000 1,145 6,000 (2,035) (3,000) (15.000) (I,ioo) (10,000) (1,145) 6,048 (32,280) 9,607 48 48 35,887 9,655 TOTAL OF FUNDS 155,746 254,102 (321,221) 86,627 KIDNEY CANCER CARE LIMIT.ED PAGE 16 FINANCIAL STATEMENTS FOR THE YEAR ENDED 30TH SEPTEMBER 2024 NOTES TO THE FtNANCIAL STATEMENTS 12. STATEMENT OF FLTr4DS - continued Restricted Funds Kidne Cancer Awareness.. wts awarded over 3 years to 2026127 for awareness campaigning. rants Uni ersi f C brid for Kidney Cancer research. Healthcare Prof ssl nal Website redevelo illent., development of a health￿e specific website. The Private donations for Research were giv¢n by members of the publi¢ specifically requesting they be used for T¢s¢aTCh. ear 13. ANALYSIS OF NBT ASSETS BETWEEN FUNDS Current y¢ar Restrirt¢d UnTestTiCted Fluids Funds 2024 2024 Total Funds 2024 Current assets Creditors due within one year 68,314 101.484 169,798 (17,039) (17,039) TOTAL 68,314 84,44S 152,759 ANALYSIS OF NET ASSETS BETWEEN FUNDS Prlor year Restricted Unrestricted Funds Fund8 2023 2023 Total Fundy 2023 Curent asset$ Creditors due within one year TOTAL 9,655 101,802 111,457 (24,830) (24,830) 9,655 76,972 86,627 14. PENSION COMMITNLENTS The charity contribiites to employees, personal pension schemes. The pension cost charge represents contributions payable by the charity to the schemes and amounted to £3,883 (2023., £23,453). Contributions totalling £353 (2023.. £380) were payable to the s¢h¢mes at the balance sheet date and are in¢luded in creditors. 15. OPERA TtNG LEASE COMMrrMENTS At 30th September 2024 the charity had commitrllents to make future minimum lease payments under non-callcellable operating leases as follows,. 2024 2023 Within l ye 7,200 12,000 16. RELATED PARTY TRANSACTIONS Total amount received from Trustees in the year wer¢ £Nil {2023., £1,650). Last yeai s receipt W8s in relation to donations received for all ¢vent ran by the charity.